Telomere length in lymphoblast cell lines derived from clinically radiosensitive cancer patients.
Approximately 1-5 percent of cancer patients suffer from significant side effects in normal tissue after radiotherapy (RT). Although RT is an effective cancer therapy, treatment dose intensities are restricted to minimize the incidence of such normal tissue reactions. Therefore, most patients receive lower dose intensities than can be tolerated in normal tissue. A primary aim for radiation oncology is to identify radiosensitive (RS) individuals prior to treatment. Such predictive ability should result in an improvement in tumor control rates and/or a reduction in the incidence of RT side effects. Recent evidence suggests a link between RS and telomere length. A positive correlation between cellular RS and telomere length in a cohort of breast cancer patients has been reported. Furthermore,individuals with cancer-prone recessive RS syndromes, such as ataxia-telangiectasia (A-T) and Nijmegen breakage syndrome(NBS), have shortened telomeres. To determine whether the association between telomere length and RS could be used as a predictive assay to prospectively identify RS cancer patients, we utilized a bank of lymphoblastoid cell lines (LCLs) derived from 33 RS patients, along with 18 LCL samples from RT patients who did not have severe reactions, to assess the link between RS and telomere length. We found a subset of RS patient LCLs had abnormally long telomere lengths, so these data suggest that RS could potentially be predicted for a subset of RS patients based on telomere length in LCLs, and contribute to therapy individualization.
Sprung
Carl N
CN
Division of Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Davey
Deborah S P
DS
Withana
Nimali P
NP
Distel
Luitpold V
LV
McKay
Michael J
MJ
D001260:Ataxia Telangiectasia / Q000235:genetics* / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D015331:Cohort Studies; D004247:DNA / Q000032:analysis; D004262:DNA Restriction Enzymes / Q000378:metabolism; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008214:Lymphocytes / Q000378:metabolism*; D009369:Neoplasms / Q000235:genetics* / Q000532:radiotherapy*; D049932:Nijmegen Breakage Syndrome / Q000235:genetics* / Q000532:radiotherapy*; D016615:Telomere / Q000648:ultrastructure*
D004247:DNA; D004262:DNA Restriction Enzymes